264 related articles for article (PubMed ID: 17919489)
1. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
[TBL] [Abstract][Full Text] [Related]
3. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
[No Abstract] [Full Text] [Related]
4. Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.
Wiegand J; Cornberg M; Aslan N; Schlaphoff V; Sarrazin C; Kubitschke A; Buggisch P; Ciner A; Jaeckel E; Manns MP; Wedemeyer H
Antivir Ther; 2007; 12(3):303-16. PubMed ID: 17591020
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics.
Kamal SM; Ismail A; Graham CS; He Q; Rasenack JW; Peters T; Tawil AA; Fehr JJ; Khalifa Kel S; Madwar MM; Koziel MJ
Hepatology; 2004 Jun; 39(6):1721-31. PubMed ID: 15185314
[TBL] [Abstract][Full Text] [Related]
6. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
Massanella M; Tural C; Papagno L; Garcia E; Jou A; Bofill M; Autran B; Clotet B; Blanco J
Antivir Ther; 2010; 15(3):333-42. PubMed ID: 20516553
[TBL] [Abstract][Full Text] [Related]
7. Concomitant augmentation of type 1 CD4+ and CD8+ T-cell responses during successful interferon-alpha and ribavirin treatment for chronic hepatitis C virus infection.
Sreenarasimhaiah J; Jaramillo A; Crippin J; Lisker-Melman M; Chapman WC; Mohanakumar T
Hum Immunol; 2003 May; 64(5):497-504. PubMed ID: 12691700
[TBL] [Abstract][Full Text] [Related]
8. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
[TBL] [Abstract][Full Text] [Related]
9. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
Martin B; Hennecke N; Lohmann V; Kayser A; Neumann-Haefelin C; Kukolj G; Böcher WO; Thimme R
J Hepatol; 2014 Sep; 61(3):538-43. PubMed ID: 24905492
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy.
Pugnale P; Herrmann E; Neumann AU; Pawlotsky JM; Schalm SW; Ferrari C; Homburger Y; Zeuzem S; Negro F;
J Hepatol; 2008 Jun; 48(6):932-8. PubMed ID: 18433918
[TBL] [Abstract][Full Text] [Related]
11. Effects of antiviral therapy on the cellular immune response in acute hepatitis C.
Rahman F; Heller T; Sobao Y; Mizukoshi E; Nascimbeni M; Alter H; Herrine S; Hoofnagle J; Liang TJ; Rehermann B
Hepatology; 2004 Jul; 40(1):87-97. PubMed ID: 15239090
[TBL] [Abstract][Full Text] [Related]
12. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
Yu ML; Dai CY; Huang JF; Chuang WL
Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
[No Abstract] [Full Text] [Related]
13. Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C.
Ferraro D; Bonura C; Giglio M; Di Stefano R; Almasio PL; Di Marco V; Craxì A; Cacciola I; Squadrito G; Raimondo G
J Biol Regul Homeost Agents; 2003; 17(2):172-5. PubMed ID: 14518718
[TBL] [Abstract][Full Text] [Related]
14. Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy.
Lauer GM; Lucas M; Timm J; Ouchi K; Kim AY; Day CL; Schulze Zur Wiesch J; Paranhos-Baccala G; Sheridan I; Casson DR; Reiser M; Gandhi RT; Li B; Allen TM; Chung RT; Klenerman P; Walker BD
J Virol; 2005 Oct; 79(20):12979-88. PubMed ID: 16189000
[TBL] [Abstract][Full Text] [Related]
15. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy.
Tang KH; Herrmann E; Cooksley H; Tatman N; Chokshi S; Williams R; Zeuzem S; Naoumov NV
J Hepatol; 2005 Nov; 43(5):776-82. PubMed ID: 16139918
[TBL] [Abstract][Full Text] [Related]
16. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C.
Cramp ME; Rossol S; Chokshi S; Carucci P; Williams R; Naoumov NV
Gastroenterology; 2000 Feb; 118(2):346-55. PubMed ID: 10648463
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
19. Clinical responders to antiviral therapy of chronic HCV infection show elevated antiviral CD4+ and CD8+ T-cell responses.
Pillai V; Lee WM; Thiele DL; Karandikar NJ
J Viral Hepat; 2007 May; 14(5):318-29. PubMed ID: 17439521
[TBL] [Abstract][Full Text] [Related]
20. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
